Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
作者信息
Yaman Samet, Bilgin Burak, Şendur Mehmet An, Hızal Mutlu, Akıncı Muhammed Bülent, Yalçın Bulent
机构信息
Department of Internal Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
出版信息
Future Oncol. 2019 Mar;15(9):925-927. doi: 10.2217/fon-2018-0503. Epub 2019 Mar 11.
PMID:30854890
Abstract
摘要
相似文献
1
Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?酪氨酸激酶抑制剂在一线转移性肾细胞癌治疗中失宠了吗？
Future Oncol. 2019 Mar;15(9):925-927. doi: 10.2217/fon-2018-0503. Epub 2019 Mar 11.
2
In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.简而言之：卡博替尼（Cabometyx）用于晚期肾细胞癌。
Med Lett Drugs Ther. 2016 Jul 18;58(1499):e97.
3
Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.既往酪氨酸激酶抑制剂对接受纳武单抗或卡博替尼治疗的转移性肾细胞癌患者生存的影响：基于文献的荟萃分析数据
Eur Urol. 2017 Dec;72(6):1027-1028. doi: 10.1016/j.eururo.2017.07.019. Epub 2017 Jul 29.
4
Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.回复：E·杰森·阿贝尔、斯蒂芬·H·卡尔普、尼扎尔·M·坦尼尔等。转移性肾细胞癌患者原发肿瘤对靶向药物的反应。《欧洲泌尿外科杂志》2011年；59卷：第10 - 5页。
Eur Urol. 2011 Jun;59(6):e34. doi: 10.1016/j.eururo.2011.02.038. Epub 2011 Mar 12.
5
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.卡博替尼在骨转移性肾细胞癌和去势抵抗性前列腺癌中的生物学问题。
Future Oncol. 2018 Oct;14(25):2559-2564. doi: 10.2217/fon-2018-0158. Epub 2018 Aug 24.
6
[First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].晚期肾细胞癌的一线治疗：一项随机II期研究，旨在比较晚期或转移性肾细胞癌患者在治疗三个月后疾病稳定时，酪氨酸激酶抑制剂早期换用纳武利尤单抗与继续使用酪氨酸激酶抑制剂治疗的效果（NIVOSWITCH - AUO的AN 38/15）
Urologe A. 2017 Apr;56(4):509-511. doi: 10.1007/s00120-017-0343-2.
7
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.阿昔替尼治疗转移性肾细胞癌：超越二线治疗。
Future Oncol. 2017 Sep;13(21):1839-1852. doi: 10.2217/fon-2017-0104. Epub 2017 Jul 14.
8
The current status of adjuvant treatment for high-risk renal cell carcinoma.高危肾细胞癌辅助治疗的现状
Future Oncol. 2017 Oct;13(23):2017-2020. doi: 10.2217/fon-2017-0352. Epub 2017 Oct 6.
9
Savolitinib for MET-driven papillary renal cell carcinoma.赛沃替尼用于MET驱动的乳头状肾细胞癌。
Lancet Oncol. 2017 Aug;18(8):e440. doi: 10.1016/S1470-2045(17)30508-9. Epub 2017 Jun 29.
10
Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan.日本不可切除或转移性肾细胞癌患者的治疗模式与治疗结果
Int J Urol. 2019 Feb;26(2):202-210. doi: 10.1111/iju.13830. Epub 2018 Oct 21.
Zotero 插件